|
influenza |
23 |
|
transmission |
20 |
|
covid-19 |
15 |
|
animals |
14 |
|
humans |
14 |
|
sars-cov-2 |
13 |
|
ferrets - virology |
12 |
|
influenza virus |
12 |
|
viral tropism |
12 |
|
conjunctiva - virology |
10 |
|
influenza a virus, h1n1 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h1n2 subtype - genetics - growth & development - pathogenicity |
10 |
|
organ culture techniques |
10 |
|
reassortant viruses - isolation & purification |
10 |
|
respiratory mucosa - virology |
10 |
|
swine |
10 |
|
tropism |
10 |
|
virulence |
10 |
|
airborne |
9 |
|
airborne transmission |
9 |
|
contamination |
9 |
|
coronavirus |
9 |
|
ferrets |
9 |
|
influenza-virus |
9 |
|
2009 pandemic h1n1 influenza virus |
8 |
|
bioaerosol |
8 |
|
conjunctiva |
8 |
|
human exhaled breath |
8 |
|
innate host responses |
8 |
|
mask |
8 |
|
swine influenza virus |
8 |
|
airborne particles |
7 |
|
h7n9 |
7 |
|
hemagglutinin glycoproteins, influenza virus - metabolism |
7 |
|
immunity |
7 |
|
influenza a |
7 |
|
influenza a virus, h1n1 subtype - enzymology - genetics - physiology |
7 |
|
neuraminidase - metabolism |
7 |
|
orthomyxoviridae infections - epidemiology - transmission - virology |
7 |
|
surveillance |
7 |
|
viral genes |
7 |
|
zoonosis |
7 |
|
aerosols |
6 |
|
avian influenza virus |
6 |
|
clade 2.3.4.4.b |
6 |
|
clinical phenotype |
6 |
|
conservation |
6 |
|
cross-reactive antibody |
6 |
|
cross-reactive antibody response |
6 |
|
influenza a virus, h1n1 subtype - genetics - pathogenicity |
6 |
|
influenza a virus, h3n2 subtype - genetics - pathogenicity |
6 |
|
influenza a(h1n1)pdm09 |
6 |
|
influenza a(h5n1) |
6 |
|
influenza, human - transmission |
6 |
|
male |
6 |
|
neuraminidase inhibition antibody |
6 |
|
neutralization |
6 |
|
orthomyxoviridae infections - transmission |
6 |
|
pandemic risk assessment |
6 |
|
pandemics |
6 |
|
respiratory infections |
6 |
|
sars coronavirus 2 |
6 |
|
seroepidemiology |
6 |
|
serology |
6 |
|
swine - virology |
6 |
|
t cell epitope |
6 |
|
vaccine |
6 |
|
virus replication |
6 |
|
viruses |
6 |
|
baloxavir |
5 |
|
c-type lectins |
5 |
|
clec5a |
5 |
|
cytotoxicity |
5 |
|
drug resistance, viral |
5 |
|
emergency department |
5 |
|
emetine |
5 |
|
environmental surveillance |
5 |
|
gamma ifn |
5 |
|
glycosylation |
5 |
|
h7n9 influenza virus |
5 |
|
hemagglutinin |
5 |
|
human density |
5 |
|
immune memory |
5 |
|
immunohistochemistry |
5 |
|
influenza a virus, h9n2 subtype - genetics - pathogenicity |
5 |
|
influenza and respiratory viruses |
5 |
|
influenza, human - virology |
5 |
|
lopinavir |
5 |
|
macrophages |
5 |
|
mutation, missense |
5 |
|
neuraminidase inhibitors |
5 |
|
nucleoprotein |
5 |
|
omicron |
5 |
|
oseltamivir |
5 |
|
pathogenicity |
5 |
|
protection |
5 |
|
r292k na mutation |
5 |
|
reassortment |
5 |
|
remdesivir |
5 |
|
resistance |
5 |
|
ritonavir |
5 |
|
rna replicase - genetics - metabolism |
5 |
|
spleen tyrosine kinase (syk) |
5 |
|
syrian hamsters |
5 |
|
temporal pattern |
5 |
|
viral proteins - genetics - metabolism |
5 |
|
virulence factors - genetics - metabolism |
5 |
|
anti-neuraminidase antibody |
4 |
|
clade 2.3.4.4b |
4 |
|
coinfection - virology |
4 |
|
droplet transmission |
4 |
|
highly pathogenic avian influenza (hpai) |
4 |
|
influenza a virus, h7n9 subtype - drug effects - genetics - isolation and purification |
4 |
|
pandemic |
4 |
|
pandemic h1n1 |
4 |
|
recombinant ha protein |
4 |
|
seasonal h1n1 |
4 |
|
sero-diagnosis |
4 |
|
tissue tropism |
4 |
|
animal |
3 |
|
animal tissue |
3 |
|
antiviral |
3 |
|
avian 18s rna |
3 |
|
avian influenza |
3 |
|
building ventilation |
3 |
|
cfd modeling |
3 |
|
chicken |
3 |
|
china |
3 |
|
close contact |
3 |
|
close-contact transmission |
3 |
|
co-infection |
3 |
|
cruise ship |
3 |
|
disease outbreaks - history |
3 |
|
downwind spread |
3 |
|
emerging or re-emerging diseases |
3 |
|
epitope mapping |
3 |
|
experiment |
3 |
|
h1n1 |
3 |
|
h5n1 |
3 |
|
h9n2 |
3 |
|
hemagglutinin glycoproteins, influenza virus - chemistry - genetics |
3 |
|
history, 20th century |
3 |
|
history, 21st century |
3 |
|
immunity, innate - physiology |
3 |
|
immunology |
3 |
|
influenza a virus - classification - isolation & purification - pathogenicity |
3 |
|
influenza a virus, h1n1 subtype - immunology |
3 |
|
influenza a virus, h5n1 subtype |
3 |
|
influenza a virus, h5n1 subtype - immunology |
3 |
|
influenza in birds - immunology - prevention and control |
3 |
|
influenza, human - epidemiology - immunology - physiopathology |
3 |
|
influenza, human - immunology - prevention and control |
3 |
|
influenza, human - mortality - pathology - virology |
3 |
|
neuraminidase |
3 |
|
niosh bioaerosol sampler |
3 |
|
nuclear magnetic resonance |
3 |
|
orthomyxoviridae - pathogenicity |
3 |
|
pathogenesis |
3 |
|
poultry |
3 |
|
receptor interaction |
3 |
|
saturation transfer difference |
3 |
|
short-range airborne |
3 |
|
transmission chain |
3 |
|
zoonotic infections |
3 |
|
adaptation, physiological - genetics |
2 |
|
adult |
2 |
|
aerosol |
2 |
|
aerosol dispersion |
2 |
|
aged |
2 |
|
air |
2 |
|
airflow |
2 |
|
antibody |
2 |
|
antigens, viral - immunology |
2 |
|
antivirals |
2 |
|
bioinformatics |
2 |
|
biology |
2 |
|
canine influenza virus |
2 |
|
clade 2.3.4.4 |
2 |
|
clinical article |
2 |
|
companion and shelter dogs |
2 |
|
computational fluid dynamics |
2 |
|
computer assisted tomography |
2 |
|
contact dynamics |
2 |
|
convalescent sera |
2 |
|
covid-19 vaccines |
2 |
|
cyclooxygenase-2 inhibitors |
2 |
|
days post-symptom onset |
2 |
|
disease transmission |
2 |
|
dose–response relationship |
2 |
|
environmental sampling |
2 |
|
epitopes |
2 |
|
exhaled breath |
2 |
|
expired droplet |
2 |
|
exposure |
2 |
|
genetic diversity |
2 |
|
hfnc |
2 |
|
highly pathogenic avian influenza virus |
2 |
|
household transmission |
2 |
|
human behavior |
2 |
|
human coronaviruses |
2 |
|
human influenza virus |
2 |
|
immediate body surfaces |
2 |
|
immunomodulators |
2 |
|
infection |
2 |
|
infectious quanta |
2 |
|
inflammation |
2 |
|
influenza a virus |
2 |
|
influenza a virus, h5n1 subtype - pathogenicity |
2 |
|
influenza in birds - immunology - virology |
2 |
|
large droplet |
2 |
|
large droplets |
2 |
|
lung |
2 |
|
microbiology |
2 |
|
multi-virion aerosol |
2 |
|
mutational spectra |
2 |
|
neuraminidase inhibitor |
2 |
|
neuraminidase inhibitor resistance |
2 |
|
niv |
2 |
|
omicron variant |
2 |
|
orthomyxoviridae infections - transmission - virology |
2 |
|
oxygen therapy |
2 |
|
peramivir |
2 |
|
polymerase fidelity |
2 |
|
population quanta |
2 |
|
power-law distribution |
2 |
|
qmra |
2 |
|
reassortant viruses - pathogenicity |
2 |
|
respiratory infection |
2 |
|
sars-cov-2 outbreak |
2 |
|
seroprevalence |
2 |
|
signal transduction |
2 |
|
surface sampling |
2 |
|
symptoms |
2 |
|
variants of concern |
2 |
|
ventilation |
2 |
|
virus |
2 |
|
wells–riley equation |
2 |
|
acetamides - administration & dosage |
1 |
|
acetamides - adverse effects - therapeutic use |
1 |
|
acetamides - pharmacology |
1 |
|
aerosol transmission |
1 |
|
amino acid sequence |
1 |
|
amino acid substitution |
1 |
|
amino acid substitution - genetics |
1 |
|
animals, wild - virology |
1 |
|
antibodies, viral - biosynthesis |
1 |
|
antigen binding |
1 |
|
antiviral agents - administration & dosage |
1 |
|
antiviral agents - pharmacology |
1 |
|
antiviral agents - therapeutic use |
1 |
|
antiviral drug |
1 |
|
binding affinity |
1 |
|
binding sites - genetics |
1 |
|
bird diseases - transmission |
1 |
|
birds - virology |
1 |
|
brain - virology |
1 |
|
bronchiole |
1 |
|
cap-dependent endonuclease inhibitor |
1 |
|
caspases - metabolism |
1 |
|
cell line |
1 |
|
cercopithecus aethiops |
1 |
|
cfd |
1 |
|
chickens |
1 |
|
chickens - virology |
1 |
|
coculture techniques |
1 |
|
cricetinae |
1 |
|
deep mutational scanning |
1 |
|
dendritic cell |
1 |
|
dendritic cells - virology |
1 |
|
diagnostic techniques and procedures - trends |
1 |
|
disease models, animal |
1 |
|
disease outbreaks |
1 |
|
disease outbreaks - prevention & control |
1 |
|
dna mutational analysis |
1 |
|
dogs |
1 |
|
dose-response relationship, drug |
1 |
|
droplet deposition |
1 |
|
drug administration schedule |
1 |
|
drug resistance, multiple |
1 |
|
drug resistance, viral - drug effects - genetics - physiology |
1 |
|
drug resistance, viral - genetics |
1 |
|
drug tolerance |
1 |
|
ducks |
1 |
|
ducks - virology |
1 |
|
ecology |
1 |
|
environment samples |
1 |
|
enzyme activation |
1 |
|
enzyme inhibitors - pharmacology |
1 |
|
enzyme inhibitors - therapeutic use |
1 |
|
enzyme stability - genetics |
1 |
|
exhalation |
1 |
|
extracellular signal-regulated map kinases - metabolism |
1 |
|
fecal aerosols |
1 |
|
female |
1 |
|
ferrets - immunology - virology |
1 |
|
fitness |
1 |
|
geese |
1 |
|
genetic variation |
1 |
|
genome, viral - genetics |
1 |
|
gtp-binding proteins - genetics - immunology |
1 |
|
guanidines |
1 |
|
guanidines - pharmacology |
1 |
|
hemagglutinin glycoproteins, influenza virus - genetics |
1 |
|
hemagglutinin glycoproteins, influenza virus - genetics - immunology |
1 |
|
hemagglutinin glycoproteins, influenza virus - genetics - metabolism |
1 |
|
hemagglutinin glycoproteins, influenza virus - genetics - physiology |
1 |
|
hemagglutinins - metabolism |
1 |
|
homes for the aged - trends |
1 |
|
hospital |
1 |
|
hydrogen-ion concentration |
1 |
|
immunization programs - trends |
1 |
|
influenza a virus (h1n1) |
1 |
|
influenza a virus (h3n2) |
1 |
|
influenza a virus - drug effects - genetics - growth & development |
1 |
|
influenza a virus - drug effects - immunology |
1 |
|
influenza a virus - drug effects - pathogenicity |
1 |
|
influenza a virus - genetics - pathogenicity - physiology |
1 |
|
influenza a virus, h1n1 subtype - enzymology - metabolism - physiology |
1 |
|
influenza a virus, h3n2 subtype - drug effects - enzymology - genetics - physiology |
1 |
|
influenza a virus, h3n2 subtype - enzymology - metabolism - physiology |
1 |
|
influenza a virus, h5n1 subtype - chemistry - genetics - pathogenicity |
1 |
|
influenza a virus, h5n1 subtype - classification - genetics - isolation & purification - pathogenicity |
1 |
|
influenza a virus, h5n1 subtype - enzymology - genetics - pathogenicity |
1 |
|
influenza a virus, h5n1 subtype - genetics - pathogenicity |
1 |
|
influenza a virus, h5n1 subtype - immunology - pathogenicity |
1 |
|
influenza a virus, h5n1 subtype - metabolism |
1 |
|
influenza a virus, h5n1 subtype - physiology |
1 |
|
influenza b virus - drug effects - immunology |
1 |
|
influenza in birds - drug therapy - genetics - pathology |
1 |
|
influenza in birds - epidemiology - virology |
1 |
|
influenza in birds - virology |
1 |
|
influenza vaccines - administration & dosage - therapeutic use |
1 |
|
influenza, human - drug therapy - epidemiology |
1 |
|
influenza, human - drug therapy - epidemiology - prevention & control |
1 |
|
influenza, human - drug therapy - genetics - pathology |
1 |
|
influenza, human - enzymology - virology |
1 |
|
influenza, human - immunology - virology |
1 |
|
influenza, human - prevention & control |
1 |
|
inhibitory concentration 50 |
1 |
|
kinetics |
1 |
|
liver - cytology - metabolism |
1 |
|
lower airways |
1 |
|
lung - cytology - metabolism |
1 |
|
lung - virology |
1 |
|
map kinase kinase kinases - metabolism |
1 |
|
map kinase signaling system - physiology |
1 |
|
membrane fusion |
1 |
|
mice |
1 |
|
mice, inbred balb c |
1 |
|
mice, inbred strains |
1 |
|
michigan - epidemiology |
1 |
|
microbial sensitivity tests - methods |
1 |
|
models, molecular |
1 |
|
mutagenesis, site-directed |
1 |
|
mutation |
1 |
|
mx1 |
1 |
|
nasal cavity - pathology - virology |
1 |
|
neuraminidase - antagonists & inhibitors - chemistry - genetics |
1 |
|
neuraminidase - antagonists & inhibitors - chemistry - metabolism |
1 |
|
neuraminidase - antagonists & inhibitors - genetics |
1 |
|
neuraminidase - antagonists & inhibitors - genetics - metabolism |
1 |
|
neuraminidase - genetics |
1 |
|
nonhuman |
1 |
|
nucleoproteins - chemistry - genetics - metabolism |
1 |
|
nursing homes - trends |
1 |
|
observation - methods |
1 |
|
organisms, genetically modified |
1 |
|
orthomyxoviridae - drug effects - enzymology - genetics - growth & development |
1 |
|
orthomyxoviridae infections - drug therapy |
1 |
|
orthomyxoviridae infections - epidemiology - immunology - pathology - transmission |
1 |
|
orthomyxoviridae infections - immunology - virology |
1 |
|
oseltamivir - pharmacology |
1 |
|
phylogeny |
1 |
|
point mutation |
1 |
|
polymerase |
1 |
|
population surveillance - methods |
1 |
|
poultry diseases - epidemiology - virology |
1 |
|
protein interaction domains and motifs - genetics |
1 |
|
protein processing, post-translational - genetics |
1 |
|
protein structure, tertiary |
1 |
|
pyrans |
1 |
|
pyrans - pharmacology |
1 |
|
raf kinases - metabolism |
1 |
|
receptors, virus - metabolism |
1 |
|
recombination, genetic |
1 |
|
reduced susceptibility |
1 |
|
ribonucleoproteins - metabolism |
1 |
|
rna replicase - antagonists & inhibitors - genetics |
1 |
|
rna replicase - genetics |
1 |
|
rna replicase - metabolism |
1 |
|
rna-binding proteins - chemistry - genetics - metabolism |
1 |
|
russia - epidemiology |
1 |
|
seasons |
1 |
|
sensitivity and specificity |
1 |
|
sialic acids - pharmacology |
1 |
|
species specificity |
1 |
|
susceptibility |
1 |
|
temperature |
1 |
|
transfection |
1 |
|
turkeys |
1 |
|
viral core proteins - chemistry - genetics - metabolism |
1 |
|
viral plaque assay |
1 |
|
viral proteins - antagonists & inhibitors - chemistry - genetics |
1 |
|
viral proteins - genetics |
1 |
|
viral proteins - metabolism |
1 |
|
virulence - genetics |
1 |
|
virulence factors - genetics |
1 |
|
virus internalization |
1 |
|
virus replication - drug effects |
1 |
|
virus replication - genetics |
1 |
|
virus shedding - immunology |
1 |
|
zanamivir |
1 |
|
zoonoses - epidemiology |
1 |
